Angiotensin blockade with eprosartan: Vascular and functional implications

Current Medical Research and Opinion, Supplement

Volumn 23, Issue 5, 2007, Pages

  Ram, C Venkata S ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Texas Blood Pressure Institute   (United States)

Author keywords

Angiotensin II type 1 receptor (AT1); Blood pressure; Cardiovascular disease; Cerebrovascular disease; Eprosartan; Hypertension; Renin angiotensin system (RAS)

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENDROFLUMETHIAZIDE; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; HYDROCHLOROTHIAZIDE; INSULIN; IRBESARTAN; LOSARTAN; NORADRENALIN; PERINDOPRIL; PLACEBO; TELMISARTAN; VALSARTAN;

BLOOD PRESSURE REGULATION; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DOSE TITRATION; DRUG EFFECT; DRUG MECHANISM; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY FUNCTION; KIDNEY STRUCTURE; MONOTHERAPY; NONHUMAN; OXIDATION; RECEPTOR BLOCKING; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; THROMBOCYTE AGGREGATION;

ACRYLATES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; ATHEROSCLEROSIS; HUMANS; IMIDAZOLES; KIDNEY DISEASES; PLATELET AGGREGATION; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM; THIOPHENES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 37849034072     PISSN: 01419951     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X260700     Document Type: Conference Paper

References (42)

1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72
2. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13
3. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA 2002;287:1003-10
4. Kaplan NM. Management of hypertensive patients with multiple cardiovascular risk factors. Am J Hypertens 2001;14:221S-224S
5. Rupp H, Jäger B. The renin-angiotensin system and the sympathetic nervous system in hypertension and congestive heart failure: implications for therapeutic interventions. J Clin Basic Cardiol 2001;4:47-51
6. Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol 1992;262:E763-78
7. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 2006;129(1 Suppl.):169S-173S
8. Verma S, Strauss M. Angiotensin receptor blocker and myocardial infarction. BMJ 2004;329:1248-9
9. Verdecchia P, Angeli F, Gattobigio R, et al. Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur Heart J 2005;26:2381-6
10. Robins GW, Scott LJ. Eprosartan: a review of its use in the management of hypertension. Drugs 2005;65:2355-77
11. Brooks DP, Ohlstein EH, Ruffolo RR, Jr. Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data. Am Heart J 1999;138: 246-51
12. Balt JC, Mathy MJ, Nap A, et al. Prejunctional and postjunctional inhibitory actions of eprosartan and candesartan in the isolated rabbit mesenteric artery. J Cardiovasc Pharmacol 2002; 40:50-7
13. Guimaraes S, Pinheiro H, Tavares P, et al. Differential effects of eprosartan and losartan at prejunctional angiotensin II receptors. Naunyn Schmiedebergs Arch Pharmacol 2001;363:509-14
14. Christensen M, Ibsen H, Worck R. Effect of eprosartan on catecholamines and peripheral haemodynamics in subjects with insulin-induced hypoglycaemia. Clin Sci (Lond) 2005;108:113-19
15. Arosio E, De MS, Prior M, et al. Haemodynamic effects of eprosartan and valsartan in hypertensive patients during isometric and mental stress. J Hypertens 2005;23:1923-7
16. Brown NJ, Vaughan DE. Prothrombotic effects of angiotensin. Adv Intern Med 2000;45:419-29
17. Liu J, Yang F, Yang XP, et al. NAD(P)H oxidase mediates angiotensin II-induced vascular macrophage infiltration and medial hypertrophy. Arterioscler Thromb Vasc Biol 2003;23:776-82
18. White WB, Anwar YA, Mansoor GA, et al. Evaluation of the 24-hour blood pressure effects of eprosartan in patients with systemic hypertension. Am J Hypertens 2001;14:1248-55
19. Punzi HA, Punzi CF. Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study. J Hum Hypertens 2004;18:655-61
20. Ruilope L, Jager B, Prichard B. Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial. Blood Press 2001;10:223-9
21. Rake EC, Breeze E, Fletcher AE. Quality of life and cough on antihypertensive treatment: a randomised trial of eprosartan, enalapril and placebo. J Hum Hypertens 2001;15:863-7
22. Antonopoulos S, Megaloikonomos P, Milonopoulou M, et al. Eprosartan vs cilazapril once daily monotherapy in mild to moderate hypertension. J Hypertens 2003;21(Suppl. 4):S133
23. Derosa G, Ragonesi PD, Mugellini A, et al. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004;27:457-64
24. Schrader J, Luders S, Kulschewski A, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36:1218-26
25. Punzi HA, Punzi CF. An 8-week, double-blind, placebo-controlled, multicenter ambulatory blood pressure monitoring study of Teveten (eprosartan mesylate) 600mg and 1200mg QD in patients with essential hypertension. 20th Annual Scientific Meeting of the American Society of Hypertension, May 14-18, 2005: San Francisco, USA
26. Aranda P, Aranda FJ, Fernandez E, et al. Long-term safety and effectiveness of eprosartan in mild-to-moderate essential hypertensive patients: EPROSYST study. J Hypertens 2003;21(Suppl. 4):66
27. de la Sierra A, Munoz A, Acros E, et al. The effect of treatment with eprosartan on pulse pressure: factors predicting response. Can J Cardiol 2004;20 (Suppl. C):17-22
28. Robles NR, Martin-Aqueda B, Lopez-Munoz F, et al. Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients. Int J Clin Pract 2005;59:478-84
29. Teitelbaum I, Chilvers M, Reiz RJS. The angiotensin receptor blocker eprosartan mesylate reduces pulse pressure in isolated systolic hypertension. Can J Cardiol 2005;20(Suppl. C):11C-16C
30. de la Sierra A, Munoz A, Arrcos E, et al. Effect of eprosartan on pulse pressure and blood pressure components in patients with isolated systolic hypertension. Blood Press 2004;13(Suppl. 2):5-10
31. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992;152:56-64
32. Rahman ST, Lauten WB, Khan QA, et al. Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation). Am J Cardiol 2002;89:686-90
33. Bogar L. Hemorheology and hypertension: not 'chicken or egg' but two chickens from similar eggs. Clin Hemorheol Microcirc 2002;26:81-3
34. Labios M, Martinez M, Gabriel F, et al. Effect of eprosartan on cytoplasmic free calcium mobilization, platelet activation, and microparticle formation in hypertension. Am J Hypertens 2004;17:757-63
35. Frank H, Schobel HP, Vitkowsky J, et al. Effects of angiotensin II receptor antagonism on the renal hemodynamic response to cardiovascular stress. Kidney Int 2003;63:617-23
36. Delles C, Jacobi J, John S, et al. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension. Kidney Int 2002;61:1462-8
37. Garg JP, Ellis R, Elliott WJ, et al. Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study. Am J Nephrol 2005;25:393-9
38. Abrahamsen CT, Barone FC, Campbell WG, Jr, et al. The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension. J Pharmacol Exp Ther 2002;301:21-8
39. Suzuki G, Mishima T, Tanhehco EJ, et al. Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure. Br J Pharmacol 2003;138:301-9
40. Diamond JA, Gharavi A, Roychoudhury D, et al. Effect of long-term eprosartan versus enalapril antihypertensive therapy on left ventricular mass and coronary flow reserve in stage I-II hypertension. Eprosartan Study Group. Curr Med Res Opin 1999;15:1-8
41. Williams B, Lacy PS, Thorn SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-25
42. Dhakam Z, McEniery CM, Yasmin, et al. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens 2006;19:214-19